Siemens Healthineers unveils restructuring plan with new precision therapy segment
Siemens Healthineers has announced a comprehensive strategic restructuring at its Capital Markets Day in London, introducing a new reporting framework centred on three distinct segments and targeting annual revenue growth of 5-7% through fiscal year 2030.
The medical technology company’s “Elevating Health Globally” strategy establishes Precision Therapy as a newly consolidated segment combining its Varian radiation oncology platform, Advanced Therapies portfolio and Ultrasound operations. This reorganisation reflects the company’s strategic focus on non-communicable diseases, particularly stroke, cancer, cardiovascular conditions and neurodegenerative disorders.
Financial targets reflect segmented approach
Under the new framework, Siemens Healthineers projects annual revenue growth of 6-9% from the combined Imaging and Precision Therapy segments during fiscal years 2027-2030. The Imaging segment, encompassing computed tomography, magnetic resonance imaging, molecular imaging, X-ray and digital automation technologies, is expected to achieve mid- to high-single-digit percentage growth with margin expansion driven by economies of scale.
The newly formed Precision Therapy segment, which includes radiation oncology, interventional oncology, mobile and fixed c-arms, ultrasound and digital oncology platforms, is projected to deliver high-single-digit percentage revenue growth annually whilst increasing margins by approximately 100 basis points on average.
The Diagnostics segment, comprising core lab solutions, specialty lab solutions and point-of-care technologies, will operate under its own strategic framework and is expected to approach mid-single-digit percentage growth, with margins expanding into the mid-teens.
Artificial intelligence positioned as clinical accelerator
The company has positioned healthcare artificial intelligence as a key enabler for addressing the growing burden of non-communicable diseases across both emerging and developed economies. The strategy emphasises AI-driven tools for patient selection and monitoring, particularly relevant given recent therapeutic developments in neurodegenerative conditions such as Alzheimer’s disease.
“In the Elevating phase of our strategy, we want to make an impact on the health of the world’s 8 billion people by fighting the diseases they fear, helping more people live with hope,” said Chief Executive Bernd Montag. “We want to take our company to the next level, using our global presence and experience to help our customers increase efficiency, drive clinical excellence and expand healthcare access.”
Value partnerships expansion and financial framework
Siemens Healthineers plans to expand its Value Partnerships model, which currently connects the company with more than 200 major customers globally. The company is developing customised Value Programmes designed to support healthcare providers in addressing specific non-communicable diseases.
